Recursion Pharmaceuticals (RXRX) Cash from Financing Activities (2020 - 2026)

Recursion Pharmaceuticals (RXRX) has 7 years of Cash from Financing Activities data on file, last reported at -$3.5 million in Q1 2026.

• Quarterly Cash from Financing Activities fell 108.56% year-over-year to -$3.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $477.5 million (up 44.38% YoY) and the FY2025 annual result came in at $521.5 million, up 71.49% from the prior year.
• Cash from Financing Activities slipped to -$3.5 million in Q1 2026, from $132.0 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $263.1 million in Q2 2024 to a low of -$3.5 million in Q1 2026.
• A 5-year average of $65.7 million and a median of $16.5 million in 2024 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities surged 6848.03% — and 2026, when it tumbled 108.56%.
• Tracing RXRX's Cash from Financing Activities over 5 years: stood at $147.3 million in 2022, then slumped by 45.23% to $80.7 million in 2023, then sank by 86.81% to $10.6 million in 2024, then soared by 1140.77% to $132.0 million in 2025, then slumped by 102.63% to -$3.5 million in 2026.
• The last three Cash from Financing Activities figures came in at -$3.5 million (Q1 2026), $132.0 million (Q4 2025), and $251.3 million (Q3 2025), per Business Quant data.